The ataxia-telangiectasia-mutated (ATM) kinase is a key transducer of DNA damage signals within the genome maintenance machinery and a tumour suppressor whose germline mutations predispose to familial breast cancer. ATM signalling is constitutively activated in early stages of diverse types of human malignancies and cell culture models in response to oncogene-induced DNA damage providing a barrier against tumour progression. As BRCA1 and BRCA2 are also components of the genome maintenance network and their mutations predispose to breast cancer, we have examined the ATM expression in human breast carcinomas of BRCA1/2 mutation carriers, sporadic cases and familial non-BRCA1/2 patients. Our results show that ATM protein expression is aberrantly reduced more frequently among BRCA1 (33%; P ¼ 0.0003) and BRCA2 (30%; P ¼ 0.0009) tumours than in non-BRCA1/2 tumours (10.7%). Furthermore, the non-BRCA1/2 tumours with reduced ATM expression were more often estrogen receptor (ER) negative (P ¼ 0.0002), progesterone receptor (PR) negative (P ¼ 0.004) and were of higher grade (P ¼ 0.0004). In our series of 1013 non-BRCA1/2 cases, ATM was more commonly deficient (20%; P ¼ 0.0006) and p53 was overabundant (47%; Po0.0000000001) among the difficult-to-treat ER/PR/ ERBB2-triple-negative subset of tumours compared with cases that expressed at least one of these receptors (10 and 16% of aberrant ATM and p53, respectively). We propose a model of 'conditional haploinsufficiency' for BRCA1/2 under conditions of enhanced DNA damage in precancerous lesions resulting in more robust activation and hence increased selection for inactivation or loss of ATM in tumours of BRCA1/2 mutation carriers, with implications for genomic instability and curability of diverse subsets of human breast cancer.
Introduction
The ataxia-telangiectasia-mutated (ATM) kinase is an apical signal transducer within the hierarchical cellular network that responds to DNA double-strand breaks and plays a critical role in maintaining genomic integrity through coordination of cell cycle checkpoints, DNA repair and cell-death pathways (Shiloh, 2003; Bartek et al., 2004; . Such pleiotropic effects of ATM are attributable to a wide range of its substrates including Chk2, p53, mdm2, NBS1, SMC1, FANCD2, Kap1, BRCA1 and others, all components of DNA damage signalling, repair, chromatin remodelling, transcriptional regulation, apoptosis and other mechanisms that together constitute the multifaceted cellular response to DNA damage (Shiloh, 2003; Ziv et al., 2006; Matsuoka et al., 2007) . Consistent with its role in genome stability maintenance, ATM is also an established tumour suppressor whose mutations or epigenetic silencing contributes to pathogenesis of a range of malignancies (Shiloh, 2003; Kastan and Bartek, 2004) . Germline mutations of ATM predispose to familial breast cancer in a subset of families that do not carry mutations in either of the two prototypic breast cancerpredisposing genes, BRCA1 or BRCA2 (Renwick et al., 2006; Pylkas et al., 2007) . In addition, defects of ATM, BRCA1 or BRCA2 also occur in some sporadic tumours (Turner et al., 2004; Prokopcova et al., 2007) .
Recently, links between the ATM-coordinated DNA damage response (DDR) and tumorigenesis have been strengthened by reports on constitutive activation of the DDR machinery in diverse types of human cancer, particularly at their early, pre-invasive stages (Gorgoulis et al., 2005; Bartkova et al., 2005a) . Given that such DDR activation was not provoked by therapy and analogous checkpoint induction was recapitulated in multiple xenograft and cell culture models of oncogene activation (Bartkova et al., 2005a (Bartkova et al., , 2006 Gorgoulis et al., 2005; Di Micco et al., 2006; Mallette et al., 2007) , these studies suggest that the DDR network may function as a biological barrier against cancer progression. Conceptually, this evidence furthermore implies that the activated DDR barrier creates growth-suppressive conditions under which inactivating aberrations within the DDR machinery are selected for, and thereby allowing such early lesions to overcome the DDR-induced senescence and/or cell-death pathways and to progress towards full malignancy.
To further understand the biological roles and clinical relevance of the DDR machinery, here we investigate the mutual relationship between aberrations of ATM and the breast cancer-related genes BRCA1 and BRCA2 and specifically address the following issues: first, during tumour progression, defects of ATM may occur in the same tumour that harbours mutant BRCA1 or BRCA2, and we asked whether ATM and BRCA1/2 defects are random or whether they tend to be associated or mutually exclusive. Second, recent advances in breast cancer-research allowed a biological subclassification of human breast tumours into several categories based on their characteristic gene-expression profiles and/or phenotypic features such as the expression of ER, PR and ERBB2 receptors (Perou et al., 2000; Sorlie et al., 2001) . Some of the underlying genetic differences are also emerging as BRCA1 tumours, BRCA2 tumours and non-BRCA1/2 tumours present different immunohistochemical characteristics and molecular features (Palacios et al., 2003) . As the identified classes of breast cancer also differ in their prognosis and responses to DNA-damaging adjuvant therapies, we argued that the status of ATM, as an important element of cellular responses to such therapies, could also contribute to the clinically observed distinct behaviour. To this end, we analysed the ATM status in a series of the so-called ER/ PR/ERBB2-triple-negative breast tumours, an emerging class of particularly difficult-to-treat carcinomas, compared with the other breast tumours.
Results and discussion
To compare the relative frequencies of aberrant reduction of the ATM protein among breast carcinomas with germline BRCA1/2 mutations (n ¼ 76) versus non-BRCA1/2 tumours (n ¼ 1106), we employed an established immunohistochemical protocol (Lukas et al., 2001; Vahteristo et al., 2002) using the monoclonal antibody ATML2p recognizing an epitope between amino acids 2581 and 2599 of ATM (a kind gift from Yossi Shiloh), previously validated for immunostaining on archival specimens of formalin-fixed and paraffin-embedded human tissues (Angele et al., 2003; Bartkova et al., 2005a, b) . Representative examples of the ATM-staining patterns in normal human breast and invasive carcinomas with either preserved or aberrantly reduced ATM expression are shown in Figure 1 . As more than 90% of epithelial cells in the normal breast tissues (n ¼ 27) were positive for the ATM protein, we considered it as aberrant reduction of ATM expression when fewer than 70% of breast cancer cells were ATM-positive in a given tumour. We also regarded ATM as aberrantly reduced when the staining intensity of the breast cancer cells was clearly lower compared with the ATM-staining signal in adjacent normal The results of the immunohistochemical analysis are summarized in Table 1 . Whereas the familial (n ¼ 740) and the sporadic (n ¼ 366) non-BRCA1/2 tumours showed similar ATM-expression there was a clear and approximately 3-fold increase of the ATM-aberrant cases among both the BRCA1 and BRCA2 tumours as compared with the non-BRCA1/2 tumours (Table 1 ). ATM acts upstream of for example BRCA1 in the same pathway, since the ATM kinase directly phosphorylates BRCA1 on serine residues S1423 and S1524, thereby modulating the function of BRCA1 (Cortez et al., 1999) . Considering the concept of the DNA damage response as an anticancer barrier, these results are consistent with a scenario where the initial cancer-predisposing defect of for example BRCA1 or BRCA2 would undermine the genome integrity control and the aberrantly increased numbers of unrepaired double-strand breaks would lead to a more robust activation of the initially wild-type ATM. This would activate the ATM-regulated cell cycle checkpoints and cell death pathways that might select for ATM inactivation if such lesions should progress towards malignancy. Thus, the BRCA1/2 defects eventually led to increased frequency of ATM 'inactivation'.
To address the second goal of our study, we investigated whether aberrantly reduced ATM expression is associated with the established clinicopathological parameters including the status of estrogen, progesterone and ERBB2 (HER2) receptors among the large series of 1106 non-BRCA1/2 breast tumours. As can be seen from the results summarized in Table 2 , the non-BRCA1/2 tumours with reduced ATM expression were significantly more often ER negative (P ¼ 0.0002), PR negative (P ¼ 0.004) and of higher grade (P ¼ 0.0004, grade 3 versus grades 1 þ 2) than the tumours with normal ATM expression.
We also examined immunohistochemical overabundance of p53, a useful marker of p53 missense mutations (Iggo et al., 1990) . The p53 tumour suppressor protein is involved in the DDR and, -like BRCA1, it is also a direct substrate of the ATM kinase (Kastan and Bartek, 2004) . Furthermore, like ATM, p53 was also found activated in early human lesions as part of the anticancer barrier (Bartkova et al., 2005a) and it is a marker which is reportedly elevated in BRCA1-deficient breast cancer and the triple-negative subset of breast tumours (Honrado et al., 2005; Cleator et al., 2007) . As can be seen from the data in Table 2 , there was no significant association of p53 overabundance (scored as positive when 20% or more cancer cells in a tumour were stained) with normal or aberrantly reduced ATM among the non-BRCA1/2 series. In BRCA1 tumours, the frequency of p53 positivity was higher than that in either BRCA2 cancers or in non-BRCA1/2 tumours, but these differences did not reach statistical significance due to small sample size (Figure 2a) . However, the subset of ER/PR/ERBB2-triple-negative breast tumours showed a very close correlation with p53 overabundance (n ¼ 142; Po0.00000001) compared to tumours expressing at least one of these three receptors (n ¼ 871).
The graphical summary of the results for both p53 and ATM analyses for non-BRCA1/2 tumours is shown in Figure 2b . Interestingly, the aberrant reduction of ATM also occurs significantly more commonly among the ER/PR/ERBB2-triple-negative tumours (P ¼ 0.0006) compared to the non-BRCA1/2 breast carcinomas that expressed at least one of the three types of receptors and showed low frequency of ATM defects (Figure 2b ). The triple-negative tumours are typically highly proliferative, poorly differentiated and display extensive genetic instability. Interestingly, the triple-negative cancers share these and multiple additional features with the BRCA1-associated breast tumours including high incidence of p53 mutations, broadly similar mRNA expression profiles and poor prognosis (Cleator et al., 2007) . Our present results indicate that the increased frequency of aberrant ATM Kilpivaara et al., 2005,) . Of the altogether 1182 invasive breast cancers, 36 tumours were from BRCA1 and 40 tumours from BRCA2 mutation positive families; 740 tumours were from other familial breast cancer patients and 366 from sporadic patients. BRCA1/2 mutations had been excluded for all the 428 cases with strong family history of cancer (three or more, first-or second-degree relatives with breast or ovarian cancer), as well as, for 154 of the 312 cases from families with two affected first-degree relatives (BRCA1/2 mutation screening described in Vehmanen et al., 1997; Vahteristo et al., 2001 Vahteristo et al., , 2002 . The study was performed with informed consents from the patients as well as permissions from the Ethics Committee (E8) of the Helsinki University Central Hospital and from the Ministry of Social Affairs and Health in Finland.
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As indicated in the introduction, the ER/PR/ERBB2-triple-negative tumours are a challenge to treat and, arguably, the most exciting implication of identification of phenotypic and genetic similarities between BRCA1-associated and triple-negative breast tumours is the emerging possibility to design novel targeted therapies to which both these classes of breast cancer might be exceptionally sensitive. A promising avenue for a tailormade treatment of BRCA1-deficient tumours is small molecule-mediated inhibition of poly (ADP-ribose) polymerase 1 (PARP1), the key element of the pathways that repair DNA single-strand breaks and hence prevent replication-associated formation of double-strand breaks. The PARP1 inhibition disables such complementary repair mechanisms and renders cells particularly dependent on homologous recombination and therefore on BRCA1/2 function. Consequently, high sensitivity to PARP1 inhibitors is observed in BRCA1/2-deficient tumours (Bryant et al., 2005; Farmer et al., 2005) , and enhanced sensitivity is also found in cells with impaired double-strand breaks signalling (McCabe et al., 2006) .
We believe that our present data have potential implications for responses to treatment such as PARP1 inhibition as well as for conceptual understanding of the role which BRCA1/2 carrier state plays in the accelerated, early-onset breast cancers. We propose (Figure 2c ) that there is an increased demand for BRCA1/2 function in DNA damage signalling and repair in the early lesions reflecting the oncogene-induced chronic replication stress and DNA breakage (Bartkova et al., 2005a (Bartkova et al., , 2006 Gorgoulis et al., 2005; Di Micco et al., 2006) . This scenario is distinct from normal tissues that are not exposed to such stress. As a result, the altered niche in the premalignant lesions likely presents levels of endogenous damage that are no more safely manageable by the DDR machinery which relies on only one functional allele of BRCA1 or BRCA2. In other words, such conditions with supra-threshold levels of constitutive DNA damage may unmask 'conditional haploinsufficiency' for BRCA1/2 in the early lesions (Figure 2c ). Under such conditions, the DDR machinery including the ATM-Chk2-p53 cascade is activated and this environment selects for inactivation of the activated DDR barrier including ATM and p53 for example. This concept is consistent with the preferential association of ATM defects with BRCA1/ 2-deficient cancers reported in this study and with the enhanced frequency of p53 and ATM-aberrations in the triple-negative breast cancers that share some features of 'BRCAness' (Turner et al., 2004; Cleator et al., 2007) . From the clinical point of view, the DNA-damagethreshold-related differences might be beneficial in response to PARP1 inhibitors and analogous drugs. Such therapy may target not only the advanced cancers with complete lack of BRCA1/2 function upon loss of the second allele of BRCA1/2 but also the conditionally deficient BRCA1/2-heterozygous cells in the precursor lesions while subthreshold levels of endogenous DNAdamage would allow resistance to such treatments in normal tissues of the patients including the BRCA1/2 mutation carriers. Elston and Ellis, 1991) and histological tumour type by one pathologist (PH). The ER and PR staining methods and evaluation of the results used in routine diagnostics are described in Eerola et al. (2005a) . Samples were considered positive when 10% of the cancer cells were positive for the staining. ERBB2 protein expression on tumours on TMAs was analysed by immunohistochemical (IHC) staining and ERBB2 gene amplification with chromogenic in situ hybridization (CISH), as previously described (Tanner et al., 2000; Lassus et al., 2004) . The ERBB2 amplification was considered negative with 2-5 copies of ERBB2 in single nucleus and positive with 6-10 copies. When CISH result was not available, unambiguous IHC result (weak/negative staining or strong positivity >90% of cells) was used. p53 protein expression was studied as previously described (Tommiska et al., 2005) . Samples were considered positive when 20% of the cancer cells were positive for the p53 staining. Statistical analysis was conducted with SPSS version 12.0.1 for Windows (SPSS Inc., Chicago, IL, USA). The differences in dichotomous variables were tested by the w 2 test or Fisher's exact test. All P-values are two-sided and P-valueo0.01 was considered significant. Figure 2 ATM and p53 expression in relation to BRCA1/2 status in breast carcinomas. (a) ATM protein expression is aberrantly reduced or lost more frequently among BRCA1 (***P ¼ 0.0003) and BRCA2 (***P ¼ 0.0009) than in non-BRCA1/2 tumours. Analogous comparisons of p53-expression did not show statistically significant differences. (b) ATM is more commonly deficient among the ER/PR/ERBB2-triple-negative subset of non-BRCA1/2 tumours (20%, 29/142) compared with cases which express at least one of these markers (10%, 86/871) (***P ¼ 0.0006). The ER/PR/ERBB2-triple-negative tumours are also more frequently p53 immunopositive than the other non-BRCA1/2 tumours (*****Po0.0000000001). (c) Speculative model of 'conditional haploinsufficiency' for BRCA1/2 during breast cancer development. The overall process that involves the DDR barrier activation is broadly analogous in all tumours, however, it is accelerated due to the supra-threshold DNA damage in the early stages of tumorigenesis in the BRCA1/2 mutation carriers leading to faster selection of DDR-defective malignant clones and thereby contributing to the early-onset pattern of such familial tumours.
